Audit: QRS - Tocopherols for Health & Longevity

Audit conducted on 11/08/2026 03:08 using AI4L + evidence-mcp / Opus 5

Iterations

Summary

Items Count
Total 93
Passed 83
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All gate items, tier items, marker rows, targets and protocol values trace to literal ER passages; verified by string comparison against the ER.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 No empty-state or hedged ER passage is carried into a populated QRS field; no such phrasing was required.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindication severity, dose thresholds and time windows are preserved at ER strength.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications come from the ER’s “Populations who should avoid” list, Key Interactions from the ER interaction bullets, Benefits/Risks from their own ER sections; no Benefit- or Risk-Modifying Factor content is surfaced.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, trial names, NCT identifiers, expert names or brand names appear anywhere in the QRS.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind are present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 British spelling and the ER’s plain-language glosses (“bleeding into the brain”, “fatty liver with inflammation”) are carried through.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Quantified targets, dose thresholds and decision gates give the reader actionable levers without editorialising.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Statements are descriptive throughout; no imperatives directed at an individual.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Content is presented as observed practice and measured ranges, not instruction.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No instances of “recommend”, “advise”, “you should” or equivalent.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address anywhere in the document.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms are limited to those the ER itself uses; acronyms in Monitoring are expanded (INR, ALT, PSA).
2.8 Information is presented in a concise and very compact manner 🟢 Tier items, gate items and marker cells are single clauses without elaboration.
2.9 It DOES NOT address the reader directly 🟢 Confirmed; no direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Biomarker targets, isoform displacement tracking and dose-threshold framing address an optimising, risk-aware reader.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 An eight-marker panel with a staged cadence assumes willingness to test and track.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Content depth (haptoglobin genotype benefit, γ-tocopherol displacement) exceeds general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 At-A-Glance makes explicit that benefit clusters where starting levels are low — the decisive signal for an already-replete optimising reader.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “Anti-aging” does not appear; the speculative benefit is phrased “slowed biological aging”.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Formal terminology throughout; the plain-language glosses in At-A-Glance are the ER’s own Conclusion wording and are mandated by item 7.4.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings, gate titles, tier labels and column headers match the template byte-for-byte.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 38 template variable spans are present; the repeatable marker_#* and qualitative_item# spans are instantiated as marker_1–8 and qualitative_item_1–6.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 A structural diff against the template shows differences confined to variable content and the metadata block; no fixed markup, CSS or static text was altered.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section mapped by this checklist is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels (“Standard maintenance dose”, “Condition-specific high dose”, “Best time of day”) and the Key Interactions bold labels are carried verbatim.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Marker names match the ER Biomarker column verbatim; Time-to-Effect labels are the only constructed labels and the ER supplies no bold label for those sub-facts.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 A character scan confirms no emoji code points anywhere in the file; the ER’s tier emoji were correctly dropped.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Eight gate items per column, eight marker rows and six qualitative items sit within the per-section budget; tier items are condensed to ER headings.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14, immediately after the doctype and before any other markup.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening “—” at line 3, closing “—” at line 13; the “QRS — Metadata” caption precedes the opening delimiter.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is repeated in rendered content.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, and it contains a colon, which requires quoting.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: tocopherols_2026-0811-0127_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: qrs_creation_date: 2026-0811-0302.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” — single word, no version or qualifier.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9 matches the actual filename tocopherols_2026-0811-0127_Opus_QRS.html.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “Tocopherols for Health & Longevity - Quick Reference Sheet”; ampersand correctly encoded.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “Tocopherols for Health & Longevity”, matching the ER canonical_topic.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0811 renders as 08/11/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 5”, matching the frontmatter.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only the title and the template subline; the ER’s alternate-names line was correctly not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses the Conclusion’s four load-bearing points: selective handling, where benefit clusters, the bleeding harm, and that dose and form decide the direction.
7.2 [at_a_glance] is no longer than 60 words 🟢 56 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each clause maps to a distinct sentence of the ER Conclusion (lines 503, 505, 507).
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms; “bleeding into the brain” and “fatty liver with inflammation” replace hemorrhagic stroke and steatohepatitis, matching the ER’s own plain-language glosses.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years or sample sizes.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No effect sizes, risk ratios or confidence intervals.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All eight items derive from the “Populations who should avoid Tocopherols” list in that ER section.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All eight ER avoid-population bullets are present, none added.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Eight <li> elements inside the stop_items span.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Items are the ER bullets unchanged; no trailing clauses, rationale or citations.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “within 14 days”, “below 100 × 10⁹/L”, “at or above 400 IU/day”, “above the recommended intake” and the NYHA class are all retained.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in this section.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 The ER names eight such populations and the section is correctly populated, not empty.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All eight items derive from the interaction bullets of that ER section.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Eight of the nine ER interaction bullets are carried; “Vitamin K antagonists” is correctly excluded because vitamin K antagonist use is already a Contraindications gate item.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Eight <li> elements inside the caution_items span.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 The “Caution;”/”Monitor;” severity words, mechanism clauses, the HATS citation and all Mitigation sentences are stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Every parenthetical drug list is retained verbatim, verified by string comparison against the ER.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in this section.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 The ER names nine interactions and the section is correctly populated, not empty.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 All three cells derive from the ER Therapeutic Protocol bullets.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Maintenance dose, condition-specific high dose and dosing timing are the three executable levers; the remaining bullets are context, bias or population modifiers.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER supplies more than three actionable aspects; all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine fields carry ER-derived content; labels are the ER bold labels verbatim and values carry the ER doses (100–200 IU/day, 800 IU/day) and timing.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Liver enzymes, dementia function and immune measures — the three outcome-linked latencies in the ER “Time to effect” bullet.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Liver (High-tier benefit) first, then dementia function and immune response (Medium tier, in ER order).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER supplies four time-to-effect facts; all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 Values 12–24 weeks, 6–12 months and 4 months match the ER exactly; the pharmacokinetic plateau is folded into time_3_sub.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information; the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All eleven items are the ER benefit sub-headings across the four tiers.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each item is the bare ER sub-heading; all Magnitude figures, trial names and the “⚠️ Conflicted” markers are dropped.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any benefit item.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items in the ER; none is empty.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All eleven items are the ER risk sub-headings across the four tiers.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each item is the bare ER sub-heading; all Magnitude figures, trial names and “⚠️ Conflicted” markers are dropped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any risk item.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items in the ER; none is empty.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 All eight rows derive from the biomarker table in Monitoring Protocol & Defining Success.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All eight ER table rows are present in ER order, with names, targets and rationale carried faithfully.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Captures baseline, the 12-week and 6–12-month intervals, the 12/24-week liver recheck and annual PSA in men, matching ER lines 461–463.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 All six items come from the ER’s “Qualitative markers worth tracking” list.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All six ER qualitative bullets are present verbatim and in ER order.

Issues 11/08/2026 03:08

Pass rate 100.00%. No issues found.